The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 473-481

  Öhlschläger, Peter ^a   Spies, Elmar ^a   Alvarez, Gerardo ^a   Quetting, Michael ^a   Groettrup, Marcus ^a,b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b UNIVERSITY OF KONSTANZ   (Switzerland)

Author keywords

cervical cancer; DNA vaccine; electroporation; gynecology; immunology; immunotherapy; tumor regression; virology

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANZYME B; PLASMID VECTOR; PROTEIN E7; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG RESPONSE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE CASSETTE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; UTERINE CERVIX CANCER;

ANIMALS; CANCER VACCINES; CELL LINE; CPG ISLANDS; ELECTROPORATION; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 78649577157     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25344     Document Type: Article

References (42)

1. Pisani S, Gallinelli C, Seganti L, Lukic A, Nobili F, Vetrano G, Imperi M, Degener AM, Chiarini F,. Detection of viral and bacterial infections in women with normal and abnormal colposcopy. Eur J Gynaecol Oncol 1999; 20: 69-73.
2. Gatta G, Lasota MB, Verdecchia A,. Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. Eur J Cancer 1998; 34 (14 Spec No): 2218-25.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV,. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
4. Dyson N, Howley PM, Munger K, Harlow E,. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
5. Munger K, Scheffner M, Huibregtse JM, Howley PM,. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992; 12: 197-217.
6. Ohlschlager P, Pes M, Osen W, Durst M, Schneider A, Gissmann L, Kaufmann AM,. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006; 24: 2880-93.
7. Babiuk LA, van Drunen Littel-van den H, Babiuk SL,. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol 1999; 72: 189-202.
8. Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, Nickerson CE, Fu T, Shiver JW, et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 2000; 74: 7485-95.
9. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-80.
10. Calarota SA, Weiner DB,. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199: 84-99.
11. Jechlinger W,. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006; 5: 803-25.
12. Tsen SW, Paik AH, Hung CF, Wu TC,. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines 2007; 6: 227-39.
13. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM,. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon Iγ. Proc Natl Acad Sci USA 1996; 93: 2879-83.
14. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC,. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-9.
15. Stacey KJ, Sweet MJ, Hume DA,. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-22.
16. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E,. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-4.
17. Tudor D, Dubuquoy C, Gaboriau V, Lefevre F, Charley B, Riffault S,. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 2005; 23: 1258-64.
18. Gronevik E, Tollefsen S, Sikkeland LI, Haug T, Tjelle TE, Mathiesen I,. DNA transfection of mononuclear cells in muscle tissue. J Gene Med 2003; 5: 909-17.
19. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB,. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
20. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D,. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-7.
21. Anwer K,. Formulations for DNA delivery via electroporation in vivo. Methods Mol Biol 2008; 423: 77-89.
22. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A,. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998; 16: 426-35.
23. Ljunggren HG, Karre K,. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985; 162: 1745-59.
24. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hammerling GJ, Rammensee HG,. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997; 27: 2391-9.
25. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM,. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
26. Klinman DM,. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-58.
27. van Duin D, Medzhitov R, Shaw AC,. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27: 49-55.
28. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T,. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36: 983-97.
29. Bauer M, Heeg K, Wagner H, Lipford GB,. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999; 97: 699-705. (Pubitemid 29356422)
30. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM,. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164: 1617-24.
31. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM,. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
32. Kimura Y, Sonehara K, Kuramoto E, Makino T, Yamamoto S, Yamamoto T, Kataoka T, Tokunaga T,. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem 1994; 116: 991-4.
33. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
34. Wagner H,. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-68.
35. Krieg AM,. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
36. Williams SG, Cranenburgh RM, Weiss AM, Wrighton CJ, Sherratt DJ, Hanak JA,. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 1998; 26: 2120-4.
37. Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA,. Delivery of DNA vaccines using electroporation. Methods Mol Med 2006; 127: 73-82.
38. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo F, Forni G,. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005; 11: 1941-52.
39. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB,. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26: 440-8.
40. Xiao T,. Innate immune recognition of nucleic acids. Immunol Res 2009; 43: 98-108.
41. Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, Heit A, Wagner H,. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003; 171: 5908-12.
42. Tudor D, Dubuquoy C, Gaboriau V, Lefevre F, Charley B, Riffault S,. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 2005; 23: 1258-64.